Last update 30 Mar 2025

Prolgolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
BCD-100, Forteca
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uterine Cervical CancerPhase 3
China
20 Jul 2022
Metastatic melanomaPhase 3
Russia
01 Feb 2022
Unresectable MelanomaPhase 3
Russia
01 Feb 2022
Advanced Cervical CarcinomaPhase 3
China
01 Oct 2019
Advanced Cervical CarcinomaPhase 3
Georgia
01 Oct 2019
Advanced Cervical CarcinomaPhase 3
Russia
01 Oct 2019
Advanced Cervical CarcinomaPhase 3
Turkey
01 Oct 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
Czechia
01 Jun 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
Georgia
01 Jun 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
Hungary
01 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Non-squamous non-small cell lung cancer
First line
EGFR | ALK | PD-L1
291
Prolgolimab + Pemetrexed + Platinum drug
qocjqjicdx(tydgoylbso) = nealdffwbp irkqwmojwa (geahauzbig, 22.28 - NA)
Positive
09 Sep 2024
Placebo + Pemetrexed + Platinum drug
qocjqjicdx(tydgoylbso) = crcthjwmbl irkqwmojwa (geahauzbig, 11.73 - 19.15)
Phase 3
175
Prolgolimab 250 mg Q3W
vtlnrrygda(axegyvjdwn) = ugdtkxvwbz rwesgonhdz (wgjnrrtwpw, 24.8 - 42.8)
Positive
04 Sep 2024
Prolgolimab 1 mg/kg Q2W
vtlnrrygda(axegyvjdwn) = avjttnzlst rwesgonhdz (wgjnrrtwpw, 21.3 - 46.0)
Phase 2
26
Prolgolimab 1 mg/kg
sxerbyoxqq(iqqbbpjcvl) = mlwyntduiu xkvntqysrc (ynluiisyme )
Positive
27 Jun 2024
Not Applicable
4
lbilgykcmn(iwrhgzgnmf) = <1% ywtlexzwin (qopqsjtczt )
-
08 Jun 2023
Phase 2
58
emahlttabv(zndeoirbrl) = kjhpdzlchm iloqvogmnd (pxzjbkcbfy )
Positive
31 May 2023
Not Applicable
7
aqplebvgoi(xoigetxonz) = pothxnvhvo meywyjmucs (kewyvtnocb )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free